NEO - NeoGenomics, Inc.
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics launched PTEN IHC CDx, the first IHC companion diagnostic test approved by the U.S. FDA for patients with prostate adenocarcinoma.
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its second quarter 2026 financial results after the close of U.S. financial markets on Tuesday, July 28, 2026.
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the appointment of Carolyn Starrett to its Board of Directors.
Authorization covers all three NEO100 programs across adult Phase 1 through Phase 2, plus pediatric studies Extends NeOnc's UAE footprint beyond NEO212 and complements ongoing U.S. development, where NEO100 holds FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations CALABASAS, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that the Department of Health – Abu Dhabi (DOH) has granted Investigational New Drug (IND) status for NEO100, the Company's lead candidate, an intranasally administered formulation of purified perillyl alcohol designed for non-invasive nose-to-brain delivery.
NeoGenomics (NEO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Neo Performance Materials Inc. (NEO:CA) Shareholder/Analyst Call Prepared Remarks Transcript
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes.
Employers Tighten Focus on AI and Human Skills as Global Tech Hiring Moderates PR Newswire MILWAUKEE, June 16, 2
Clearance enables Phase 2 evaluation of NEO212, the Company's oral perillyl alcohol-temozolomide conjugate, in the United Arab Emirates Follows completion of Phase 1 dose escalation and selection of 610 mg as the recommended Phase 2 dose Adds an international clinical pathway alongside continuing U.S. FDA discussions on a potential registrational pathway for NEO212 CALABASAS, Calif., June 16, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that the Department of Health – Abu Dhabi (DOH) has granted Investigational New Drug (IND) status for NEO212, the Company's orally administered perillyl alcohol-temozolomide carbamate conjugate being developed for patients with aggressive brain tumors.
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes.
On May 28, 2026, NeoGenomics Inc (NEO) shares rose 6.5% today, closing at $10.19. This movement comes amid a 52-week trading range between $4.72 and $13.74, ref
The base shelf prospectus is accessible, and the prospectus supplement will be accessible within two business days through SEDAR+ The base shelf prospectus is accessible, and the prospectus supplement will be accessible within two business days through SEDAR+
Strategic partnership positions Greenland Mines to lead exploration while Neo retains equity stake and offtake rights Strategic partnership positions Greenland Mines to lead exploration while Neo retains equity stake and offtake rights
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company will participat
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company will participate in the following investor conferences: The 23rd Annual Craig-Hallum Institutional Investor Conference in Minneapolis Investor 1x1 meetings on Thursday, May 28th The Jefferies Global Healthcare Conference 2026 in New York Fireside chat on Thursday, June 4th, at 10:30am EDT, and investor 1x1 meetings A w.
Neo Performance Materials Inc. (NEO:CA) Q1 2026 Earnings Call Transcript
NEO-CYT marks the first evaluation of MDNA11 in earlier-stage cancers, as a potentially curative treatment; extends development beyond the heavily pretreated metastatic setting of the ongoing Phase 1/2 ABILITY-1 study
CALABASAS, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing innovative therapies for central nervous system cancers, today announced that Chief Executive Officer, Executive Chairman, and President Amir Heshmatpour has significantly increased his personal ownership through consistent open-market purchases, including substantial buying in recent weeks, underscoring strong alignment with shareholders ahead of upcoming clinical and regulatory milestones.
NeoGenomics, Inc. (NEO) Q1 2026 Earnings Call Transcript
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its first-quarter results for the period ended March 31, 2026.